Dyne Therapeutics (DYN) Chardan's 8th Annual Genetic Medicines Conference summary

Business and financial overview

• Raised over $800 million in 2024, providing strong funding for clinical and registration efforts.

• Two major programs are advancing toward product launches in the next few years, with a robust pipeline built on a versatile platform.

• Recent executive hires, including experts in global product launches and rare diseases, strengthen the team for upcoming challenges.

• Focus on building a long-term, globally competitive company with multiple modalities (siRNA, ASO, PMO, enzyme) on a single platform.

Clinical program updates and data insights

• Both lead programs (DMD and DM1) show early and significant functional benefits, with improvements seen in months rather than years.

• DMD program (exon 51) demonstrated robust efficacy and functional improvement at 20 mg/kg, now set as the registration dose.

• Safety events at higher DMD doses led to dose adjustments, but the 20 mg/kg dose is supported by strong data and regulatory engagement.

• DM1 program shows dose-dependent splicing correction, with early functional and quality-of-life improvements; moving toward registration cohorts.

Regulatory and strategic direction

• Registration cohorts for DMD are being initiated, with SV95C as a primary endpoint accepted by European regulators and under FDA consideration.

• DM1 program received FDA feedback supporting CASI as an approvable endpoint for accelerated approval, with broader functional measures being tracked.

• Exploring a basket approach for additional DMD exon-skipping programs to accelerate development and expand the franchise.

• FSHD program (siRNA) is in IND-enabling studies, leveraging platform versatility and aiming for rapid clinical entry.